fr [Internet]. [cité 14 févr 2016]. Disponible sur: https ,
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children, Clin Cancer Res Off J Am Assoc Cancer Res. nov, vol.3, issue.11, pp.1985-92, 1997. ,
Pharmacokinetics of ifosfamide and some metabolites in children, Anticancer Res. juin, vol.18, issue.3B, pp.1941-1950, 1998. ,
Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide, British Journal of Cancer, vol.47, issue.1, pp.15-26, 1983. ,
DOI : 10.1038/bjc.1983.2
Activated oxazaphosphorines are transported predominantly by erythrocytes, Ann Oncol Off J Eur Soc Med Oncol ESMO. nov, vol.8, issue.11, pp.1139-1183, 1997. ,
The Neurotoxicity and Pharmacokinetics of Oral Ifosfamide, Journal of Analytical Oncology, vol.4, issue.1, pp.13-23, 2015. ,
DOI : 10.6000/1927-7229.2015.04.01.3
Pharmacokinetics of ifosfamide, Clinical Pharmacology & Therapeutics, vol.17, issue.4, pp.492-500, 1975. ,
DOI : 10.1002/cpt1975174492
Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites, Clinical Pharmacokinetics, vol.11, issue.11, pp.41-62, 2001. ,
DOI : 10.2165/00003088-200140010-00004
Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide, Journal of Cancer Research and Clinical Oncology, vol.128, issue.7, pp.385-92, 2002. ,
DOI : 10.1007/s00432-002-0335-4
Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines, Drug Metab Dispos Biol Fate Chem. déc, vol.25, issue.12, pp.1436-1477, 1997. ,
Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy, Cancer Gene Therapy, vol.10, issue.8, pp.571-82, 2003. ,
DOI : 10.1038/sj.cgt.7700601
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma, Cancer Res, vol.49, issue.3, pp.753-760, 1989. ,
Metabolism and Pharmacokinetics of Oxazaphosphorines, Clinical Pharmacokinetics, vol.5, issue.4, pp.291-304, 2000. ,
DOI : 10.2165/00003088-200038040-00001
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites, Drug Metab Dispos Biol Fate Chem. juill, vol.29, issue.7, pp.967-75, 2001. ,
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion, Cancer Chemotherapy and Pharmacology, vol.45, issue.1, pp.53-60, 1995. ,
DOI : 10.1007/BF00685732
Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation, Haematologica. avr, vol.76, issue.2, pp.120-125, 1991. ,
Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics, IARC Sci Publ, issue.78, pp.269-79, 1986. ,
Side Effects of Ifosfamide, Oncology, vol.65, issue.2, pp.7-10, 2003. ,
DOI : 10.1159/000073351
Neurological Toxicity of Ifosfamide, Oncology, vol.65, issue.2, pp.11-17, 2003. ,
DOI : 10.1159/000073352
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center, Journal of Oncology Pharmacy Practice, vol.38, issue.3, pp.188-93, 2015. ,
DOI : 10.1177/1078155214527143
Unexpected toxicity in patients treated with Iphosphamide, Cancer Res, vol.32, issue.5, pp.921-925, 1972. ,
Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention, Annals of Oncology, vol.17, issue.suppl 4, pp.33-39, 2006. ,
DOI : 10.1093/annonc/mdj997
DECHLOROETHYLATION OF IFOSFAMIDE AND NEUROTOXICITY, The Lancet, vol.328, issue.8517, pp.1219-1239, 1986. ,
DOI : 10.1016/S0140-6736(86)92227-0
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724), European Journal of Cancer (1965), vol.12, issue.3, pp.195-203, 1976. ,
DOI : 10.1016/0014-2964(76)90241-3
Ifosfamide induced stress response in human lymphocytes, Molecular Aspects of Medicine, vol.14, issue.3, pp.281-287, 1993. ,
DOI : 10.1016/0098-2997(93)90016-7
Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes, Biochemical Pharmacology, vol.46, issue.9, pp.1621-1627, 1993. ,
DOI : 10.1016/0006-2952(93)90332-Q
Chloroacetaldehyde-induced hepatocyte cytotoxicity, Biochemical Pharmacology, vol.48, issue.5, pp.1025-1057, 1994. ,
DOI : 10.1016/0006-2952(94)90374-3
Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats, J Pharmacol Exp Ther. mai, vol.289, issue.2, pp.820-824, 1999. ,
Identification of thiodiglycolic acid, thiodiglycolic acid sulfoxide, and (3-carboxymethylthio)lactic acid as major human biotransformation products of S-carboxymethyl-L-cysteine, Drug Metab Dispos Biol Fate Chem. févr, vol.19, issue.1, pp.222-228, 1991. ,
Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats, Drug Metab Dispos Biol Fate Chem. mars, vol.26, issue.3, pp.193-199, 1998. ,
Croonian Lecture: Lethal Synthesis, Proceedings of the Royal Society B: Biological Sciences, vol.139, issue.895, pp.143-70, 1952. ,
DOI : 10.1098/rspb.1952.0001
Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons, J Pharmacol Exp Ther. déc, vol.299, issue.3, pp.1161-1169, 2001. ,
Pharmacokinetics of ifosfamide, 2-and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide, Anticancer Res. oct, vol.16, issue.5B, pp.3247-57, 1996. ,
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue, The Lancet, vol.343, issue.8900, pp.763-767, 1994. ,
DOI : 10.1016/S0140-6736(94)91839-2
Editorial: The enigma of ifosfamide encephalopathy, Annals of Oncology, vol.3, issue.9, pp.679-81, 1992. ,
DOI : 10.1093/oxfordjournals.annonc.a058317
Ifosfamide Clinical Pharmacokinetics, Clinical Pharmacokinetics, vol.26, issue.6, pp.439-56, 1994. ,
DOI : 10.2165/00003088-199426060-00003
Aprepitant-associated ifosfamide neurotoxicity, J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. juin, vol.16, issue.2, pp.137-145, 2010. ,
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant, Journal of Oncology Pharmacy Practice, vol.23039, issue.3, pp.157-62, 2008. ,
DOI : 10.1177/1078155208093930
Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question, Curr Pharm Des. août, vol.5, issue.8, pp.665-72, 1999. ,
Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy, Drug Metab Dispos Biol Fate Chem. sept, vol.26, issue.9, pp.883-90, 1998. ,
Encephalopathy after High-Dose Ifosfamide, Drug Safety, vol.121, issue.39, pp.989-96, 2008. ,
DOI : 10.2165/00002018-200831110-00003
Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy, Annals of Oncology, vol.18, issue.4, pp.808-817, 2007. ,
DOI : 10.1093/annonc/mdm104
URL : http://annonc.oxfordjournals.org/cgi/content/short/18/4/808
Medication???induced mitochondrial damage and disease, Molecular Nutrition & Food Research, vol.46, issue.7, pp.780-788, 2008. ,
DOI : 10.1002/mnfr.200700075
The double-edged sword: Neurotoxicity of chemotherapy, Blood Reviews, vol.29, issue.2 ,
DOI : 10.1016/j.blre.2014.09.012
Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants, Toxicology and Applied Pharmacology, vol.198, issue.2, pp.164-83, 2004. ,
DOI : 10.1016/j.taap.2003.10.010